Featured Articles - September 7, 2021
Secretome signature of cardiopoietic cells echoed in rescued infarcted heart proteome
D. Kent Arrell, et al., STEM CELLS Translational Medicine
The secretome of clinical trial-biobanked cardiopoietic cells was here decoded. The mined (cardiomyo)vasculogenic systems signature was echoed in the response of cell recipients demonstrating disease rescue. The present clinomics study links innate secretome traits with outcome.
Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells
Paul Jäger, et al., STEM CELLS
Bone marrow (BM) failure is a characteristic clinical feature of acute myeloid leukemia (AML) causing significant morbidity and mortality. Previous work in mice suggested that AML cells functionally inhibit healthy hematopoietic stem and progenitor cells (HSPC). Now, these findings are implemented into the human system using an in vitro system modeling the in vivo situation of BM infiltration by AML. By exposing healthy CD34+ HSPC to AML patient-derived supernatants, among other secreted factors in particular TGFβ1, inhibits key functions of CD34+ HSPC, which can be blocked as therapeutic target to improve hematopoiesis in AML patients.
A new study describes the first case of G-CSF-mobilized autologous CD34-positive cell transplantation as a treatment for acute kidney injury
A study describes the requirement of Lef-1 for proper airway basal cell function and reports the possibility of modulating Lef-1 function to improve lung-based regenerative medicine
Metabolic glycoengineering of adipose-derived MSCs and enhanced isolation techniques generate exosomes that may represent a means of treating rheumatoid arthritis
Regenerative Medicine Manufacturing Society (RMMS) is partnering with STEM CELLS Translational Medicine to build a freely accessible collection of shared resources across three areas: models; cell therapies; and technologies. These resources will bring together the scientific community and highlight how the field of regenerative medicine is uniquely positioned to fight the COVID-19 pandemic.